Faculty profile

Marcel Bally

ResearcherExperimental TherapeuticsUniversity of British Columbia

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.

Marcel Bally

Researcher

Experimental Therapeutics

Health Sciences

University of British Columbia

Vancouver, British Columbia, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
4 publications in the last five years, latest in 2026.
Senior (last) author on 1 recent paper, a sign of leading a research group.
Principal investigator on 8 research grants (8 CIHR), most recently in 2024.
Supervised 2 trainees who won CIHR awards, most recently in 2012.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Liposomes Copper Metal Chemistry Drug Development Cancer Combinations Icd-Immunogenic Cell Death Immune Check Point Inhibitors (Cpis)

Latest papers

A novel liposomal formulation of irinotecan comprising a combination of copper complexation and a transmembrane pH gradient to significantly improve irinotecan encapsulation and retention.
International journal of pharmaceutics · 2026 · senior author
Cryo-EM-guided subtractive optimization of a novel VCP/p97 inhibitor.
IUCrJ · 2026
Spatial characterization of redox processes and speciation of Ru(III) anticancer complexes by 19F magnetic resonance imaging.
Chemical communications (Cambridge, England) · 2023

All 16 publications

Latest funding

Copper Associated Immunogenic Cell Death: Improving the Therapeutic Potential of Immune Check Point Inhibitors for the Treatment of Metastatic Bladder Cancer
CIHR · 2024 · Nominated PI
$1,028,926
A Novel Formulation of the Anticancer Drug Candidate CX5461 that Relies on Metal Chemistry and Liposomal Nanotechnology: Development for use in Treatment of Pancreatic Cancer's with BRCA Deficiencies; an Orphan Indication
CIHR · 2021 · Nominated PI
$765,000
Control of ER-mitochondria contacts and mitophagy by the Gp78 ubiquitin ligase: Role in tumor progression
CIHR · 2016 · Co-investigator
$1,070,300

All 24 grants and awards

16 publications.

A novel liposomal formulation of irinotecan comprising a combination of copper complexation and a transmembrane pH gradient to significantly improve irinotecan encapsulation and retention.

Sun X, Sharifiaghdam M, Sarrami N, Popescu I, Wretham N, Santos ND, Sutherland B, Leung AWY, Redelmeier T, Abram M, Bally M

International journal of pharmaceutics2026Senior author

DOI: 10.1016/j.ijpharm.2026.127024 PMID: 42191000

Cryo-EM-guided subtractive optimization of a novel VCP/p97 inhibitor.

Crawford J, Munuganti R, Leung C, Singh K, Gates E, Zhu X, Bally M, Santos ND, Sharifiaghdam M, Nosrati Z, Axerio-Cilies P, Berezuk AM, Cholak S, Merk A, Cameron DR, Subramaniam S

IUCrJ2026

DOI: 10.1107/s2052252526004604 PMID: 42329166

Spatial characterization of redox processes and speciation of Ru(III) anticancer complexes by 19F magnetic resonance imaging.

MacNeil GA, Chang SW, Prosser KE, Ye E, Heroux D, Lewis AR, Bally M, Walsby CJ

Chemical communications (Cambridge, England)2023

DOI: 10.1039/d2cc04830b PMID: 36537324

Ferrocene-appended anthraquinone and coumarin as redox-active cytotoxins.

Houshmand A, Heroux D, Liu DY, Zhou W, Linington RG, Bally M, Warren JJ, Walsby CJ

Dalton transactions (Cambridge, England : 2003)2022

DOI: 10.1039/d2dt01251k PMID: 35822497

Gold-Protein Composite Nanoparticles for Enhanced X-ray Interactions: A Potential Formulation for Triggered Release.

van Ballegooie C, Man A, Pallaoro A, Bally M, Gates BD, Yapp DT

Pharmaceutics2021

DOI: 10.3390/pharmaceutics13091407 PMID: 34575482

Inter-Metastatic Heterogeneity of Tumor Marker Expression and Microenvironment Architecture in a Preclinical Cancer Model.

Kalra J, Baker J, Song J, Kyle A, Minchinton A, Bally M

International journal of molecular sciences2021Senior author

DOI: 10.3390/ijms22126336 PMID: 34199298

Preparation of parenteral nanocrystal suspensions of etoposide from the excipient free dry state of the drug to enhance in vivo antitumoral properties.

Martin B, Seguin J, Annereau M, Fleury T, Lai-Kuen R, Neri G, Lam A, Bally M, Mignet N, Corvis Y

Scientific reports2020

DOI: 10.1038/s41598-020-74809-z PMID: 33093456

Concomitant Chemoradiation Therapy with Gold Nanoparticles and Platinum Drugs Co-Encapsulated in Liposomes.

Charest G, Tippayamontri T, Shi M, Wehbe M, Anantha M, Bally M, Sanche L

International journal of molecular sciences2020

DOI: 10.3390/ijms21144848 PMID: 32659905

The cyanobacterial metabolite nocuolin a is a natural oxadiazine that triggers apoptosis in human cancer cells.

Voráčová K, Hájek J, Mareš J, Urajová P, Kuzma M, Cheel J, Villunger A, Kapuscik A, Bally M, Novák P, Kabeláč M, Krumschnabel G, Lukeš M, Voloshko L, Kopecký J, Hrouzek P

PloS one2017

DOI: 10.1371/journal.pone.0172850 PMID: 28253280

Precision autophagy: Will the next wave of selective autophagy markers and specific autophagy inhibitors feed clinical pipelines?

Lebovitz CB, DeVorkin L, Bosc D, Rothe K, Singh J, Bally M, Jiang X, Young RN, Lum JJ, Gorski SM

Autophagy2015

DOI: 10.1080/15548627.2015.1078962 PMID: 26506897

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2024

Subject: Prospective PhD student: Liposomes Dear Professor Bally, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "A novel liposomal formulation of irinotecan comprising a combination of copper complexation and a transmembrane pH gradient to significantly improve irinotecan encapsulation and retention." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Copper Associated Immunogenic Cell Death: Improving the Therapeutic Potential of Immune Check Point Inhibitors for the Treatment of Metastatic Bladder Cancer" (2024), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Marcel Bally

Research

Latest papers

Latest funding

A novel liposomal formulation of irinotecan comprising a combination of copper complexation and a transmembrane pH gradient to significantly improve irinotecan encapsulation and retention.

Cryo-EM-guided subtractive optimization of a novel VCP/p97 inhibitor.

Spatial characterization of redox processes and speciation of Ru(III) anticancer complexes by 19F magnetic resonance imaging.

Ferrocene-appended anthraquinone and coumarin as redox-active cytotoxins.

Gold-Protein Composite Nanoparticles for Enhanced X-ray Interactions: A Potential Formulation for Triggered Release.

Inter-Metastatic Heterogeneity of Tumor Marker Expression and Microenvironment Architecture in a Preclinical Cancer Model.

Preparation of parenteral nanocrystal suspensions of etoposide from the excipient free dry state of the drug to enhance in vivo antitumoral properties.

Concomitant Chemoradiation Therapy with Gold Nanoparticles and Platinum Drugs Co-Encapsulated in Liposomes.

The cyanobacterial metabolite nocuolin a is a natural oxadiazine that triggers apoptosis in human cancer cells.

Precision autophagy: Will the next wave of selective autophagy markers and specific autophagy inhibitors feed clinical pipelines?

Copper Associated Immunogenic Cell Death: Improving the Therapeutic Potential of Immune Check Point Inhibitors for the Treatment of Metastatic Bladder Cancer

A Novel Formulation of the Anticancer Drug Candidate CX5461 that Relies on Metal Chemistry and Liposomal Nanotechnology: Development for use in Treatment of Pancreatic Cancer's with BRCA Deficiencies; an Orphan Indication

Control of ER-mitochondria contacts and mitophagy by the Gp78 ubiquitin ligase: Role in tumor progression

Copper Drug Complexes: Development of a novel class of drugs with significant potential for treatment of platinum insensitive cancers

Targeted radiopharmaceuticals to improve cancer diagnosis and treatment

Preclinical evaluation of a gentamicin analog as a treatment for genetic diseases and cancer due to a premature termination codon.

The biology and clinical significance of the tumour microenvironment in B cell lymphomas

Lipid nanomedicines for health and disease

Simultaneous chemotherapy and radiation treatment in solid tumours: A new platform to promote synergy and therapeutic efficacy with radiation triggered drug release

Somatic mutations in the JAK-STAT signaling pathway in primary mediastinal large B cell lymphoma

Frequent collaborators

Shoukat Dedhar

Andrew Minchinton

Sriram Subramaniam

David Huntsman

Calvin Roskelley

Xiaoyan Jiang